What were Zim Laboratories Ltd's latest quarterly results?
Zim Laboratories Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: -23.4% (stable)
- Revenue Growth YoY: -3.2%
- Operating Margin: 6.8% (volatile)
Zim Laboratories Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +88.3%Very Weak4w StreakRe-Entry
In , Zim Laboratories Ltd (Pharma - Formulators) is outperforming Nifty 500 with +88.3% relative strength. Fundamentals: Very Weak. On a 4-week streak.
Zim Laboratories Ltd Key Facts
- PE Ratio
- 154.0x
- Market Cap
- ₹669 Cr
- PAT Growth YoY
- -23%
- Revenue Growth YoY
- -3%
- OPM
- 6.8%
- RS vs Nifty 500
- +88.3%
PE: At PeakDanger Bubble
What's Happening
⚠️PE rising despite falling earnings — price running ahead of reality
💰Trading 96% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
-23%
Stable
Revenue YoY
-3%
Stable
Operating Margin
6.8%
-660 bps YoY
PE Ratio
154.0
Current Price
₹125
Fundamental Score
15/100
Very Weak
3Y PAT CAGR
-37%
Market Cap
669 Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Zim Laboratories Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -3% | -2% | Stable |
| PAT (Net Profit) | -23% | -37% | Stable |
| OPM | 6.8% | -660 bps | Volatile |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Zim Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Zim Laboratories Ltd's profit growing or declining?
Zim Laboratories Ltd's profit is declining with an stable trend.
- PAT Growth YoY: -23.4% (latest quarter)
- PAT Growth QoQ: -15.0% (sequential)
- 3-Year PAT CAGR: -37.0%
- Trend: Stable — consistent growth pattern
What is Zim Laboratories Ltd's revenue growth trend?
Zim Laboratories Ltd's revenue growth trend is stable.
- Revenue Growth YoY: -3.2%
- Revenue Growth QoQ: -3.1% (sequential)
- 3-Year Revenue CAGR: -2.1%
How is Zim Laboratories Ltd's operating margin trending?
Zim Laboratories Ltd's operating margin is volatile.
- Current OPM: 6.8%
- OPM Change YoY: -6.6% basis points
- OPM Change QoQ: -5.0% basis points
What is Zim Laboratories Ltd's 3-year profit and revenue CAGR?
Zim Laboratories Ltd's long-term compounding rates
- 3-Year Profit CAGR: -37.0%
- 3-Year Revenue CAGR: -2.1%
Is Zim Laboratories Ltd's growth accelerating or decelerating?
Zim Laboratories Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -33.4% bps
- Sequential Acceleration: -65.0% bps
- Margin Warning: Operating margins are under pressure
What is Zim Laboratories Ltd's trailing twelve month (TTM) performance?
Zim Laboratories Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹6 Cr
- TTM PAT Growth: -51.9% YoY
- TTM Revenue: ₹374 Cr
- TTM Revenue Growth: -1.2% YoY
- TTM Operating Margin: 8.0%
Is Zim Laboratories Ltd overvalued or undervalued?
Zim Laboratories Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 154.0x
- Price-to-Book: 2.3x
What is Zim Laboratories Ltd's current PE ratio?
Zim Laboratories Ltd's current PE ratio is 154.0x.
- Current PE: 154.0x
- Market Cap: 669 Cr
How does Zim Laboratories Ltd's valuation compare to its history?
Zim Laboratories Ltd's current PE is 154.0x.
- Current PE: 154.0x
- Valuation Assessment: Significantly Overvalued
What is Zim Laboratories Ltd's price-to-book ratio?
Zim Laboratories Ltd's price-to-book ratio is 2.3x.
- Price-to-Book (P/B): 2.3x
- Book Value per Share: ₹55
- Current Price: ₹125
Is Zim Laboratories Ltd a fundamentally strong company?
Zim Laboratories Ltd is rated Very Weak with a fundamental score of 15/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: -3.2% (10% weight)
- PAT Growth YoY: -23.4% (10% weight)
- PAT Growth QoQ: -15.0% (10% weight)
- Margins stable (10% weight)
Is Zim Laboratories Ltd debt free?
Zim Laboratories Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹127 Cr
What is Zim Laboratories Ltd's return on equity (ROE) and ROCE?
Zim Laboratories Ltd's return ratios over recent years
- FY2024: ROCE 10.0%
- FY2025: ROCE 8.0%
- FY2026: ROCE 5.0%
Is Zim Laboratories Ltd's cash flow positive?
Zim Laboratories Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹50 Cr
- Free Cash Flow (FCF): ₹-5 Cr
- CFO/PAT Ratio: 833% (strong cash conversion)
What is Zim Laboratories Ltd's dividend yield?
Zim Laboratories Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹125
Who holds Zim Laboratories Ltd shares — promoters, FII, DII?
Zim Laboratories Ltd's shareholding pattern (Mar 2026)
- Promoters: 30.4%
- FII (Foreign): 0.0%
- DII (Domestic): 0.1%
- Public: 69.6%
Is promoter holding increasing or decreasing in Zim Laboratories Ltd?
Zim Laboratories Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 30.4% (Mar 2026)
- Previous Quarter: 33.3% (Dec 2025)
- Change: -2.91% (decreasing — worth monitoring)
How long has Zim Laboratories Ltd been outperforming Nifty 500?
Zim Laboratories Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Zim Laboratories Ltd a new momentum entry or an established outperformer?
Zim Laboratories Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Is Zim Laboratories Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Zim Laboratories Ltd may be worth studying
- Cash flow is positive — CFO ₹50 Cr
What is the investment thesis for Zim Laboratories Ltd?
Zim Laboratories Ltd investment thesis summary:
Risk Factors (Bear Case)
- Margins under pressure
- Appears significantly overvalued
What is the future outlook for Zim Laboratories Ltd?
Zim Laboratories Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.